LSL Pharma GroupTSXV:LSL 49 EBITDA Margin % is -8.89% as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 49/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, LSL Pharma Group ranks worse than 74.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. LSL Pharma Group's EBITDA for the
three
months ended in Mar. 2026 was C$-1.09 Mil. LSL Pharma Group's Revenue for the
three
months ended in Mar. 2026 was C$12.30 Mil. Therefore, LSL Pharma Group's EBITDA margin for the quarter that ended in Mar. 2026 was -8.89%.
LSL Pharma Group (TSXV:LSL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
LSL Pharma Group EBITDA Margin % Related Terms
LSL Pharma Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group (TSXV:LSL) has a EBITDA Margin % of -8.89% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LSL Pharma Group and its competitors. According to the industry distribution chart, LSL Pharma Group ranks #712 out of 955 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is LSL Pharma Group's EBITDA Margin % too high?
LSL Pharma Group's current EBITDA Margin % is -8.89%. Based on the distribution chart, LSL Pharma Group ranks #712 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, LSL Pharma Group has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #712 out of 955 companies for EBITDA Margin %. This places LSL Pharma Group in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current EBITDA Margin % is -8.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 55.6% below its estimated fair value. The current EBITDA Margin % is -8.89%. LSL Pharma Group's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current EBITDA Margin % is -8.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.32 is trading 55.6% below its estimated GF Value™ of C$0.72.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
EBITDA Margin %: -8.89%
GF Value™: C$0.72 vs. price of C$0.32 (55.6% below fair value)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score
Get the complete analysis for TSXV:LSL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
